AR117707A1 - Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf - Google Patents
Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegfInfo
- Publication number
- AR117707A1 AR117707A1 ARP190103687A ARP190103687A AR117707A1 AR 117707 A1 AR117707 A1 AR 117707A1 AR P190103687 A ARP190103687 A AR P190103687A AR P190103687 A ARP190103687 A AR P190103687A AR 117707 A1 AR117707 A1 AR 117707A1
- Authority
- AR
- Argentina
- Prior art keywords
- vegf antibody
- high concentration
- protein solution
- formulation containing
- solution formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica acuosa que comprende al menos 50 mg/ml hasta aproximadamente 120 mg/ml de un anticuerpo anti-VEGF que comprende las secuencias de SEQ ID Nº 1 y SEQ ID Nº 2, aproximadamente 4,5% a 11% (p/v) sacarosa, 5 - 20 mM citrato de sodio, y 0,001% a 0,05% polisorbato 80 (p/v), en donde el pH de la composición es de aproximadamente 7,0 hasta aproximadamente 7,6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781003P | 2018-12-18 | 2018-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117707A1 true AR117707A1 (es) | 2021-08-25 |
Family
ID=69165422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103687A AR117707A1 (es) | 2018-12-18 | 2019-12-16 | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11945859B2 (es) |
| EP (1) | EP3897714A1 (es) |
| JP (2) | JP7089121B2 (es) |
| KR (1) | KR20210106476A (es) |
| CN (1) | CN113194993A (es) |
| AR (1) | AR117707A1 (es) |
| AU (1) | AU2019407063B2 (es) |
| BR (1) | BR112021011290A2 (es) |
| CA (1) | CA3119241A1 (es) |
| CL (1) | CL2021001587A1 (es) |
| CO (1) | CO2021007830A2 (es) |
| CR (1) | CR20210318A (es) |
| EC (1) | ECSP21043639A (es) |
| IL (1) | IL283456A (es) |
| JO (1) | JOP20210152A1 (es) |
| MX (1) | MX2021007393A (es) |
| PE (1) | PE20211602A1 (es) |
| SG (1) | SG11202104653XA (es) |
| WO (1) | WO2020128792A1 (es) |
| ZA (1) | ZA202102986B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2307458T1 (en) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
| PL2307457T5 (pl) | 2008-06-25 | 2022-12-27 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące tnf |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL2307457T5 (pl) | 2008-06-25 | 2022-12-27 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące tnf |
| DK3216803T3 (da) | 2008-06-25 | 2020-06-02 | Novartis Ag | Stabile og opløselige antistoffer, der hæmmer vegf |
| SI2307458T1 (en) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
| US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| EP2721048A1 (en) | 2011-06-16 | 2014-04-23 | Lonza Ltd | A process for extraction of peptides and its application in liquid phase peptide synthesis |
| KR20140045440A (ko) | 2011-06-30 | 2014-04-16 | 제넨테크, 인크. | 항-c-met 항체 제제 |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| KR20200131839A (ko) | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
-
2019
- 2019-12-16 MX MX2021007393A patent/MX2021007393A/es unknown
- 2019-12-16 BR BR112021011290A patent/BR112021011290A2/pt unknown
- 2019-12-16 PE PE2021000916A patent/PE20211602A1/es unknown
- 2019-12-16 JO JOP/2021/0152A patent/JOP20210152A1/ar unknown
- 2019-12-16 SG SG11202104653XA patent/SG11202104653XA/en unknown
- 2019-12-16 CR CR20210318A patent/CR20210318A/es unknown
- 2019-12-16 KR KR1020217021741A patent/KR20210106476A/ko unknown
- 2019-12-16 JP JP2021534608A patent/JP7089121B2/ja active Active
- 2019-12-16 US US16/715,580 patent/US11945859B2/en active Active
- 2019-12-16 CA CA3119241A patent/CA3119241A1/en active Pending
- 2019-12-16 AU AU2019407063A patent/AU2019407063B2/en active Active
- 2019-12-16 WO PCT/IB2019/060859 patent/WO2020128792A1/en active Application Filing
- 2019-12-16 AR ARP190103687A patent/AR117707A1/es unknown
- 2019-12-16 CN CN201980081759.8A patent/CN113194993A/zh active Pending
- 2019-12-16 EP EP19836538.9A patent/EP3897714A1/en active Pending
-
2021
- 2021-05-04 ZA ZA2021/02986A patent/ZA202102986B/en unknown
- 2021-05-25 IL IL283456A patent/IL283456A/en unknown
- 2021-06-15 CO CONC2021/0007830A patent/CO2021007830A2/es unknown
- 2021-06-16 CL CL2021001587A patent/CL2021001587A1/es unknown
- 2021-06-16 EC ECSENADI202143639A patent/ECSP21043639A/es unknown
-
2022
- 2022-04-20 JP JP2022069588A patent/JP2022105056A/ja active Pending
-
2024
- 2024-02-16 US US18/444,288 patent/US20240182554A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11945859B2 (en) | 2024-04-02 |
| IL283456A (en) | 2021-07-29 |
| MX2021007393A (es) | 2021-09-23 |
| US20240182554A1 (en) | 2024-06-06 |
| US20200190179A1 (en) | 2020-06-18 |
| WO2020128792A1 (en) | 2020-06-25 |
| ECSP21043639A (es) | 2021-07-30 |
| EP3897714A1 (en) | 2021-10-27 |
| KR20210106476A (ko) | 2021-08-30 |
| PE20211602A1 (es) | 2021-08-18 |
| BR112021011290A2 (pt) | 2021-11-03 |
| JP2022513253A (ja) | 2022-02-07 |
| JP7089121B2 (ja) | 2022-06-21 |
| CL2021001587A1 (es) | 2022-02-11 |
| ZA202102986B (en) | 2024-08-28 |
| CN113194993A (zh) | 2021-07-30 |
| AU2019407063A1 (en) | 2021-05-27 |
| CA3119241A1 (en) | 2020-06-25 |
| JOP20210152A1 (ar) | 2023-01-30 |
| CO2021007830A2 (es) | 2021-06-21 |
| SG11202104653XA (en) | 2021-07-29 |
| TW202031289A (zh) | 2020-09-01 |
| AU2019407063B2 (en) | 2024-07-04 |
| JP2022105056A (ja) | 2022-07-12 |
| CR20210318A (es) | 2021-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117707A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| ECSP19062769A (es) | Formulación de anticuerpo monoclonal anti-vrs | |
| NZ730821A (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| AR050353A1 (es) | Composicion de anticuerpo her2 | |
| KR950703987A (ko) | G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf) | |
| PE20050586A1 (es) | Preparacion farmaceutica que comprende un anticuerpo contra el receptor egfr | |
| AR076748A1 (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamiento | |
| AR111229A1 (es) | Formulación acuosa de anticuerpo | |
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| PE20230116A1 (es) | Formulacion de anticuerpos | |
| BR112022003169A2 (pt) | Formulações de anticorpo anti-il-23p19 | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| AR115365A1 (es) | Formulaciones de anticuerpos anti-pd-l1 humanos | |
| AR118853A1 (es) | Formulaciones farmacéuticas que contienen proteínas de fusión fc de dominio extracelular de cd80 | |
| AR119805A1 (es) | Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
| UY39083A (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria | |
| AR109252A1 (es) | Formulaciones de anticuerpos | |
| AR119680A2 (es) | Métodos de tratamiento o prevención de trastornos relacionados con el colesterol | |
| AR127813A1 (es) | FORMULACIONES FARMACEUTICAS QUE COMRENDEN Fab-PEG |